


**Product Name** : JNT-517  
**Cat. No.** : PC-25026  
**CAS No.** : 2837993-05-0  
**Molecular Formula** : C<sub>18</sub>H<sub>22</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>  
**Molecular Weight** : 418.39  
**Target** : Monoamine Transporter  
**Solubility** : 10 mM in DMSO



### Biological Activity

JNT-517 (Repinatrabit, JNT517) is a highly selective, first-in-class, orally bioavailable inhibitor of SLC6A19 (B0AT1) with IC<sub>50</sub> of 47 nM against human SLC6A19 in the isoleucine transport assay.

JNT-517 (Repinatrabit) potently inhibits the transport of glutamine in human intestinal epithelial cells with endogenous expression levels of SLC6A19 (IC<sub>50</sub> = 81 nM).

JNT-517 (Repinatrabit) does not inhibit either SLC1A5, SLC7A5, or SLC6A8 at 35 μM.

JNT-517 (Repinatrabit) also shows negligible activity against mouse SLC6A19 (IC<sub>50</sub> > 11.8 μM).

JNT-517 (Repinatrabit) is found to be safe and well tolerated and increased the urinary excretion of Phe in a phase 1 healthy volunteer study.

### References

Wobst HJ, et al. JCI Insight. 2024 Nov 8;9(21):e182876.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com